WO2010006521A1 - 2-甲基-5H-吡唑并[1,5-a][3,1]苯并噁嗪-5-亚胺化合物及其制备方法和用途 - Google Patents
2-甲基-5H-吡唑并[1,5-a][3,1]苯并噁嗪-5-亚胺化合物及其制备方法和用途 Download PDFInfo
- Publication number
- WO2010006521A1 WO2010006521A1 PCT/CN2009/070905 CN2009070905W WO2010006521A1 WO 2010006521 A1 WO2010006521 A1 WO 2010006521A1 CN 2009070905 W CN2009070905 W CN 2009070905W WO 2010006521 A1 WO2010006521 A1 WO 2010006521A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- compared
- preparation
- dpph
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- the invention belongs to the field of medicinal chemistry, and particularly relates to a 2-mercapto-5-imino-benzo[d][1,3]oxazine [5-b]pyrazole compound, a preparation method thereof and use thereof. Background technique
- Thrombosis is the pathological basis of cardiovascular and cerebrovascular diseases with moderate disability and high mortality. It is a pathological process involving blood vessels, blood and blood flow. Thrombosis and coagulation system, endothelial cell function and cell adhesion dysfunction. And so on. Antithrombotic drugs include anticoagulants, antiplatelet agents, and drugs that target endothelial cells.
- platelet GP li b / Ilia receptor antagonists have the monoclonal antibody abciximab, synthetic peptide receptor antagonists such as Eptifibatide; non-peptide receptor antagonists such as the cycloheptapeptide tirofiban and the non-peptide mimetic 1 anifiban.
- the arachidonic acid metabolism system can lead to an increase in the production of free radicals, and the peroxidation of unsaturated fatty acids in the membrane phospholipids can cause damage to the cell membrane, which will aggravate the dysfunction of brain cells.
- Cerebrospinal protection is an important part of stroke treatment.
- the brain protection agent edaravone is recommended based on evidence-based medicine, which has injected new vitality into the treatment of stroke.
- Clinical studies have shown that edaravone is effective in improving the prognosis of patients with acute cerebral infarction (within 72 hours), especially within 24 hours of onset. (Edaravone)
- the object of the present invention is to provide a pharmaceutically acceptable compound 2-mercapto-5-imino-benzo[d][1,3]oxazine[5-b]pyrazole or a pharmaceutically acceptable compound thereof Salt.
- Another object of the present invention is to provide a process for the preparation of the above compounds.
- a further object of the present invention is to provide a use of the above compound or a pharmaceutically acceptable salt thereof.
- the object of the invention can be achieved by the following measures:
- the pharmaceutically acceptable salt thereof refers to a salt in the general sense which is formed by reacting the above compound with a generally pharmaceutically acceptable acid or base without any side effects and capable of increasing the physicochemical properties (such as water solubility, etc.) of the compound.
- Acid or alkali is often selected from hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, succinic acid, maleic acid, fumaric acid, acetic acid, citric acid, tartaric acid, benzoic acid, benzenesulfonic acid, naphthalenesulfonic acid, hydrogen.
- a preparation method of the compound of the formula II is: the compound M is reacted with acetoacetate under basic conditions to prepare a compound N, and the compound N is obtained by ring-closing under the action of hydrogen chloride gas.
- the reaction equation is as follows:
- the reaction solvent may be selected from an alcohol such as ethanol or decyl alcohol; the base in the alkaline condition is generally selected from sodium alkoxide such as sodium decoxide or sodium ethoxide; and the reaction temperature is 40 to 80 °C.
- the solvent for the second step is dichlorosilane or tetrahydrofuran, and the reaction temperature is 20 to 40 °C.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be used in the pharmaceutical field, for example, in the treatment or prevention of cardiovascular and cerebrovascular diseases.
- TR 2-mercapto-5-imino-benzo[d][1,3]oxazine[5-b]pyrazole
- Figure 1 is a DPPH standard curve.
- Figure 2 is a graph showing the relationship between anti-DPPH free radical ability and reaction time.
- Figure 3 A histogram of the effects of TR on the symptoms of neurological deficits.
- Figure 5 Histogram of the effect of TR on cerebral infarct size.
- Figure 6 Bar graph of the effect of TR on the symptoms of neurological deficits.
- X+SD *P ⁇ 0.05, compared with sham surgery; #P ⁇ 0.05, compared with the model group.
- Figure 7 Bar graph of the effect of TR on brain water content.
- Figure 8 Bar graph of the effect of TR on brain tissue SOD (U/mgprot) activity.
- Figure 9 Histogram of the effect of TR on brain tissue MDA (nmol/mgprot) content.
- Diphenyl picryl radical (DPPH) spectrophotometry is a simple method for screening antioxidants Law. The principle is to use the characteristic absorption peak of DPPH solution at 517nm. When there is a radical scavenger, the absorption of the radical scavenger is gradually disappeared due to the single electron pairing with DPPH, and the degree of fading is quantified with the number of electrons it accepts. Relationship, the antioxidant activity of the sample can be evaluated by scavenging the amount of DPPH, and thus can be quantitatively analyzed by spectrometry.
- the DPPH was accurately weighed, placed in a 100 ml volumetric flask, and made up to 100 ml with 95% ethanol, and its absorbance (A) was measured at 517 nm.
- the DPPH was accurately weighed, placed in a 100 ml volumetric flask, and made up to 100 ml with 95% ethanol to prepare a DPPH solution.
- Preparation of reagent solution Accurately weigh the reagent, place it in a 100ml volumetric flask, dissolve it with 20ml of 95% ethanol, adjust pH to about 7.5, and then make up to 100ml with 95% ethanol.
- Compound 1 is: 2-indolyl-benzo[d][1,3]oxazine[5-b]pyrazol-5-one
- Compound 2 is: 2-indolyl-5- Imino-benzo[d][1,3]oxazine[5-b]pyrazole (ie TR)
- compound 3 is: 1-(2-carboxyphenyl)-3-indolylpyrazole-5 -ketone.
- the middle cerebral artery (MCAO) model of SD rats was prepared by internal carotid artery suture method, which caused cerebral ischemia-reperfusion injury.
- the drug was administered once every 0.5 hours after ischemia-reperfusion, and once every 2 hours thereafter, for a total of 3 times.
- the symptoms of neurological deficit were observed 48 hours after cerebral ischemia, and the animals were sacrificed to obtain brain infarct size and brain damage.
- 2-mercapto-5- Imino-benzo[d][1,3]oxazine [5-b]pyrazole (TR for short) is an object, with nimodipine as a reference.
- the cerebral infarct size of each group is shown in Table 5 and Figure 4.
- the cerebral infarct size of each group is shown in Table 5 and Figure 4.
- Table 5 Effect of TR on cerebral infarct size
- the scores of the severity of neurological deficit symptoms are shown in Table 1 and Figure 1.
- the symptoms of neurological deficits were significantly alleviated.
- the results indicate that TR can improve the symptoms of neurological deficits in cerebral ischemia-reperfusion animals.
- Model group 11 1 1 9 3. 0 ⁇ 0. 00* Sham group 9 0 0 9 0. 0 ⁇ 0. 00 Nimodipine group 10 3 0 7 0. 4 1. 3 ⁇ 0. 86*"
- the brain water content of each group is shown in Table 8 and Figure 7.
- the brain water content of each group is shown in Table 8 and Figure 7.
- Model group 11 1 1 9 3. 4 ⁇ 0. 90* Sham group 9 0 0 9 -0. 1 ⁇ 0. 18 Nimodipine group 10 3 0 7 0. 4 1. 6 ⁇ 0. 59* s
- TR can significantly improve the symptoms of neurological deficits in cerebral ischemia-reperfusion animals in a dose-dependent manner, reduce the area of cerebral infarction, reduce the degree of brain injury, reduce brain edema, and inhibit Lipid peroxidation of damaged brain tissue, the effective dose is 3mg/kg.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011517738A JP5345213B2 (ja) | 2008-07-18 | 2009-03-20 | 2−メチル−5H−ベンゾ[d]ピラゾロ[5,1−b][1,3]オキサジン−5−イミン化合物及びその調製方法並びに使用 |
US13/054,674 US7973036B2 (en) | 2008-07-18 | 2009-03-20 | 2-methyl-5-imino-benzo[D][1 ,3]oxazin[5-B]pyrazole compound, preparation and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008100223146A CN101318968A (zh) | 2008-07-18 | 2008-07-18 | 一种苯并噁嗪并吡唑类及开环化合物 |
CN200810022314.6 | 2008-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010006521A1 true WO2010006521A1 (zh) | 2010-01-21 |
Family
ID=40179265
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2008/071769 WO2010006485A1 (zh) | 2008-07-18 | 2008-07-25 | 一种苯并噁嗪并吡唑类及开环化合物 |
PCT/CN2009/070905 WO2010006521A1 (zh) | 2008-07-18 | 2009-03-20 | 2-甲基-5H-吡唑并[1,5-a][3,1]苯并噁嗪-5-亚胺化合物及其制备方法和用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2008/071769 WO2010006485A1 (zh) | 2008-07-18 | 2008-07-25 | 一种苯并噁嗪并吡唑类及开环化合物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7973036B2 (zh) |
JP (1) | JP5345213B2 (zh) |
CN (2) | CN101318968A (zh) |
WO (2) | WO2010006485A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973036B2 (en) | 2008-07-18 | 2011-07-05 | Qingdao Huanghai Pharmaceutical Co., Ltd | 2-methyl-5-imino-benzo[D][1 ,3]oxazin[5-B]pyrazole compound, preparation and use thereof |
US8522624B2 (en) | 2011-03-02 | 2013-09-03 | Cameron International Corporation | System and method for pressure balancing a flow meter |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101830831B (zh) * | 2010-05-25 | 2013-06-12 | 青岛黄海制药有限责任公司 | 一种制备邻肼基苯甲腈的方法 |
CN101966146B (zh) * | 2010-09-15 | 2012-07-18 | 青岛黄海制药有限责任公司 | 一种药物组合物溶液及其制备方法和用途 |
CN108912142B (zh) * | 2018-08-08 | 2021-06-18 | 延边大学 | 吡咯并苯并恶嗪酮类化合物及其注射剂和在抗血栓中的用途 |
CN111116608B (zh) * | 2020-01-10 | 2022-02-11 | 南京医科大学 | 一类具有自由基清除作用的n-苄基苯胺衍生物及其药物用途 |
WO2024050800A1 (zh) * | 2022-09-09 | 2024-03-14 | 南京中瑞药业有限公司 | 一种蛋白磷酸酶激动剂和应用 |
CN117055658B (zh) * | 2023-10-11 | 2024-01-02 | 江苏徕德生物医药有限公司 | 用于泰瑞拉奉结晶生产过程的自适应温度控制系统及方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101318968A (zh) * | 2008-07-18 | 2008-12-10 | 青岛黄海制药有限责任公司 | 一种苯并噁嗪并吡唑类及开环化合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004091441A (ja) * | 2002-09-04 | 2004-03-25 | Mitsubishi Pharma Corp | ピラゾロン誘導体を含有する経口投与製剤 |
JP2004300153A (ja) * | 2003-03-20 | 2004-10-28 | Kiyoshi Kurokawa | 蛋白修飾物生成抑制剤 |
TW200710091A (en) * | 2005-04-11 | 2007-03-16 | Tibotec Pharm Ltd | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors |
JPWO2006129524A1 (ja) * | 2005-06-03 | 2008-12-25 | 株式会社レナサイエンス | カルボニル化合物除去材 |
-
2008
- 2008-07-18 CN CNA2008100223146A patent/CN101318968A/zh active Pending
- 2008-07-25 WO PCT/CN2008/071769 patent/WO2010006485A1/zh active Application Filing
-
2009
- 2009-03-20 US US13/054,674 patent/US7973036B2/en not_active Expired - Fee Related
- 2009-03-20 WO PCT/CN2009/070905 patent/WO2010006521A1/zh active Application Filing
- 2009-03-20 JP JP2011517738A patent/JP5345213B2/ja not_active Expired - Fee Related
- 2009-03-20 CN CN2009101298163A patent/CN101508696B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101318968A (zh) * | 2008-07-18 | 2008-12-10 | 青岛黄海制药有限责任公司 | 一种苯并噁嗪并吡唑类及开环化合物 |
Non-Patent Citations (2)
Title |
---|
KANETY, HANNAH ET AL.: "Bimanes. 10. Photochemical rearrangement of 1,5-diazabicyclo[3.3.0]octa-3,7-diene-2,6-diones (9,10-dioxa-anti-bimanes)", JOURNAL OF ORGANIC CHEMISTRY, vol. 47, no. 2, 1982, pages 207 - 13 * |
VEIBEL, STIG ET AL.: "Pyrazole studies. II. Anhydrides of 1-(2-carboxyphenyl)-3-phenyl-5-pyrazolone and 1-(2-carboxyphenyl)-3-methyl-4-ethyl-5-pyrazolone", ACTA CHEMICA SCANDINAVICA, no. 2, 1948, pages 921 - 6 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973036B2 (en) | 2008-07-18 | 2011-07-05 | Qingdao Huanghai Pharmaceutical Co., Ltd | 2-methyl-5-imino-benzo[D][1 ,3]oxazin[5-B]pyrazole compound, preparation and use thereof |
US8522624B2 (en) | 2011-03-02 | 2013-09-03 | Cameron International Corporation | System and method for pressure balancing a flow meter |
US8522623B2 (en) | 2011-03-02 | 2013-09-03 | Cameron International Corporation | Ultrasonic flowmeter having pressure balancing system for high pressure operation |
Also Published As
Publication number | Publication date |
---|---|
CN101508696B (zh) | 2011-04-06 |
US20110118247A1 (en) | 2011-05-19 |
US7973036B2 (en) | 2011-07-05 |
JP2011528323A (ja) | 2011-11-17 |
CN101318968A (zh) | 2008-12-10 |
JP5345213B2 (ja) | 2013-11-20 |
WO2010006485A1 (zh) | 2010-01-21 |
CN101508696A (zh) | 2009-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010006521A1 (zh) | 2-甲基-5H-吡唑并[1,5-a][3,1]苯并噁嗪-5-亚胺化合物及其制备方法和用途 | |
US20120077760A1 (en) | Novel salts of sitagliptin | |
BR112020009975A2 (pt) | formas sólidas de um inibidor de calicreína de plasma e sais dos mesmos | |
TW201429473A (zh) | 腫瘤溶解症候群之治療劑及預防劑 | |
WO2013029431A1 (zh) | 苯并二氮杂卓衍生物的托西酸盐及其多晶型、它们的制备方法和用途 | |
CN102603723B (zh) | 阿齐沙坦有机胺盐及其制备方法和用途 | |
WO2015043453A1 (zh) | 伏立康磷酸酯钠水合物及其多晶型 | |
TW201043226A (en) | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof | |
CA2634871A1 (en) | Treatment of renal disorders, diabetic nephopathy and dyslipidemias | |
CN114081881B (zh) | 一种有机酸锂氨基酸盐、晶型、组合物及应用 | |
WO2019218864A1 (zh) | 一种2-(α羟基戊基)苯甲酸的有机胺酯衍生物药物 | |
CN104013619A (zh) | 复方氨基酸注射液18aa-v的药物组合物和用途 | |
JP6738350B2 (ja) | 尿酸輸送体阻害剤のナトリウム塩およびその結晶形 | |
CN104418818B (zh) | 帕瑞昔布钠无水化合物 | |
CN102030709B (zh) | 用作加压素受体拮抗剂的苯并氮杂卓类化合物 | |
JP4578576B2 (ja) | ガチフロキサシン含有水性液剤 | |
KR101798605B1 (ko) | 철 결핍 증상 및 철 결핍성 빈혈의 치료 및 예방을 위한 Fe(III) 착화합물 | |
WO2012139422A1 (zh) | 新型抗血小板化合物的加成盐 | |
CN104147003A (zh) | 复方氨基酸注射液17aa-i的药物组合物和用途 | |
WO2009123098A1 (ja) | ガチフロキサシン含有水性液剤、その製造方法、および、該水性液剤の低温保存および凍結融解時の沈殿生成を抑制する方法 | |
CN103462888B (zh) | 一种取代的β-环糊精包合的长春西汀注射液及其制备方法 | |
CN102532107A (zh) | 4-取代苯胺基-7-取代烷氧高哌嗪基-喹唑啉衍生物及其制备方法和用途 | |
AU2010277947A1 (en) | R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl- 6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial | |
CN105481725B (zh) | L-精氨酸苯乙酸盐的晶型及其制备方法 | |
WO2023123468A1 (zh) | 心脑血管药物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09797368 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2011517738 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13054674 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09797368 Country of ref document: EP Kind code of ref document: A1 |